hackint0sh/New-Dataset huggingface dataset:
The following intervention will consist of four osteopathic manipulation techniques (OMT) being performed that target the somatic dysfunctions associated with TOS. These techniques include: 1) Direct Thoracic Inlet Myofascial Release (TIMFR); 2) Direct Muscle Energy for the Scalene Muscles; 3) Direct Muscle Energy for the Pectoralis Muscles; and 4) Supraclavicular Fascial Release. primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Osteopathic Manipulative Treatment (OMT) measure: Blood flow changes in the upper extremity. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06273956 id: bleeding scores in ItP briefTitle: Explore the Relationship Between Platelet Count and Bleeding Score in ITP overallStatus: RECRUITING date: 2022-04-10 date: 2025-10-10 date: 2025-12-30 date: 2024-02-23 date: 2024-02-23 name: Assiut University class: OTHER briefSummary: Assessment of bleeding scores in immune thrombocytopenia purpuria to explore the relationship between platelet count and bleeding score in immune thrombocytopenia purpura (ITP) and compare the clinical practicability of bleeding grading systems with adult patients with ITP. conditions: ITP - Immune Thrombocytopenia studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED measure: explore the relationship between platelet count and bleeding assessment systems (ITP Bleeding Assessment Tool (ITP -BAT) and ITP Bleeding Scale (IBLS) in Patients with ITP to measure severity of bleeding sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Aml Sayed Hamed status: RECRUITING city: Assiut country: Egypt name: Rania Mohammed Mahmoud Hafez, professor role: CONTACT phone: +201000019198 email: raniahafez@aun.edu.eg name: Yousreyia Abdel Rahman Ahmed, professor role: CONTACT phone: +201223971307 email: dr_yousryeia@yahoo.com lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06273930 id: AFID briefTitle: Reduction of Dentine Hypersensitivity After Use of Different Dentifrices acronym: Dentrifices overallStatus: RECRUITING date: 2024-02-01 date: 2024-10-15 date: 2024-10-30 date: 2024-02-23 date: 2024-02-23 name: Armed Forces Institute of Dentistry, Pakistan class: OTHER briefSummary: To assess the impact of the use of 5% Calcium Sodium Phosphosilicate or 8% Arginine dentifrices on dentinal hypersensitivity following non-surgical periodontal therapy in patients with periodontitis. conditions: Sensitivity, Tooth studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 87 type: ESTIMATED name: 5% CALCIUM SODIUM PHOSPHOSILICATE name: 8% Arginine measure: To assess the impact on Dentinal hypersensitivity following the use of 5% CSPS or 8% Arginine following non-surgical periodontal therapy in patients with Periodontitis by VAS. measure: To assess the impact on Dentinal hypersensitivity following the use of 5% CSPS or 8% Arginine following non-surgical periodontal therapy in patients with Periodontitis by Schiff scale. sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AFID status: RECRUITING city: Rawalpindi country: Pakistan name: Muhammad J Iqbal role: CONTACT lat: 33.6007 lon: 73.0679 hasResults: False
nctId: NCT06273917 id: FY23_Pilot2_Dresden briefTitle: Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia acronym: IMPACT overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-01 date: 2025-01-01 date: 2024-02-23 date: 2024-02-23 name: National Institute on Aging (NIA) class: NIH name: Brown University briefSummary: Aim 1: To demonstrate the feasibility by determining proportion of completed medication reconciliation, Central Nervous System active Potentially Inappropriate Medication (CNS PIM) use among patients with Alzheimer's Disease and Related Dementias (ADRD) and Mild Cognitive Impairment (MCI) in the emergency department (ED), and communication between ED clinical pharmacists and outpatient prescribers.
Aim 3: To demonstrate the acceptability of the PRIDE intervention to outpatient clinicians using the Acceptability of Intervention Measure and qualitative analysis of responses. conditions: Dementia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 290 type: ESTIMATED name: PRIDE measure: Pharmacist communication of deprescribing recommendation measure: Medication reconciliation measure: Medication supply of CNS PIMs measure: Outpatient follow up measure: Repeat Emergency Department visits sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northwestern Memorial Hospital city: Chicago state: Illinois zip: 60611 country: United States name: Scott Dresden, Dr. role: CONTACT phone: 312-926-6494 email: sdresden@nm.org name: Anuva Fellner role: CONTACT phone: 312-926-8816 email: anuva.fellner@nm.org lat: 41.85003 lon: -87.65005 facility: Northwestern Medicine Lake Forest Hospital city: Lake Forest state: Illinois zip: 60045 country: United States name: Timothy Loftus role: CONTACT phone: 312-926-6612 email: timothy.loftus@northwestern.edu lat: 42.25863 lon: -87.84063 facility: Northwestern Medicine Palos Hospital city: Palos Heights state: Illinois zip: 60463 country: United States name: JiHun Lee, DO role: CONTACT phone: 708-923-5811 email: jihun.lee@nm.org lat: 41.66809 lon: -87.79644 hasResults: False
nctId: NCT06273904 id: Pro00132631 briefTitle: Modulating Escape Using Focused Ultrasound overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-09 date: 2025-12 date: 2024-02-23 date: 2024-02-23 name: Medical University of South Carolina class: OTHER briefSummary: This is a study to find out if a cutting-edge technology called transcranial focused ultrasound (tFUS) can be used to treat how people with anxiety or related concerns cope with emotional situations. tFUS is a brain stimulation technology that causes temporary changes in the activity of deep brain areas without a need for any surgery or other permanent or invasive procedures.
This study is recruiting participants who recently started treatment for anxiety or a related concern to come in for 3 visits at the Medical University of South Carolina. At the first visit, participants will do interviews and surveys asking about anxiety and related concerns, and they do tasks where they respond to emotional pictures while brain activity is measured using magnetic resonance imaging (MRI). At the next two visits, participants again do a task where they see and react to emotional images, and this time the task is done once before and again once after receiving tFUS that either actively causes temporary changes (lasting for about an hour) in a targeted brain area or is not active (no changes elicited). At each tFUS visit, responses are measured with sensors worn on the hand, arms, face, and head (these visits do not involve MRI).
Each visit in this study is expected to last between 2 - 3 hours. This study is not a treatment study, but it could help improve treatment in the future. Participants in this study are paid for their time. conditions: Anxiety Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 40 type: ESTIMATED name: Active transcranial focused ultrasound (tFUS) name: Sham transcranial focused ultrasound (tFUS) measure: Change in Fear-Potentiated Startle Reflex measure: Change in speed to initiate avoidance behavior measure: Change in Electroencephalography (EEG)-Assessed Contingent Negative Variation During Escape/ Avoidance Preparation measure: Change in Electroencephalography (EEG)-Assessed N200 During Implicit Approach/ Avoid Bias Assessment measure: Change in Electroencephalography (EEG)-Assessed Theta-Band Power During Behavioral Tasks measure: Change in High-Frequency Heart Rate Variability/ Respiratory Sinus Arrhythmia measure: Change in Task-Based Heart Rate (Beats per Minute) Changes measure: Change in Task-Based Galvanic Skin Conductance measure: Change in State Anxiety During Session measure: Task-Related Regional Brain Activation sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of South Carolina city: Charleston state: South Carolina zip: 29425 country: United States lat: 32.77657 lon: -79.93092 hasResults: False
nctId: NCT06273891 id: INOVA-2023-58 briefTitle: Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes acronym: PRACET overallStatus: RECRUITING date: 2024-03-08 date: 2025-08-01 date: 2025-10-01 date: 2024-02-23 date: 2024-03-15 name: Inova Fairfax Hospital class: OTHER briefSummary: The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. Participants diagnosed with PPROM will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. Studying these two drugs will help decide the best care for future patients with PPROM. conditions: Premature Rupture of Membrane studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 140 type: ESTIMATED name: Erythromycin name: Azithromycin measure: Latency period sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Inova Fairfax Medical Campus status: RECRUITING city: Falls Church state: Virginia zip: 22042 country: United States name: Ellen M Murrin, DO role: CONTACT phone: 703-776-6040 email: ellen.murrin@inova.org name: Antonio Saad, MD, MBA role: PRINCIPAL_INVESTIGATOR name: Ellen M Murrin, DO role: PRINCIPAL_INVESTIGATOR lat: 38.88233 lon: -77.17109 hasResults: False
nctId: NCT06273878 id: RS1439/20 briefTitle: From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy overallStatus: RECRUITING date: 2023-01-15 date: 2025-01-15 date: 2025-01-15 date: 2024-02-23 date: 2024-02-23 name: Regina Elena Cancer Institute class: OTHER name: Università degli Studi dell'Insubria briefSummary: Non-interventional retro-prospective study on Endometrial tissue samples taken from surgically treated patients. conditions: Endometrial Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 80 type: ESTIMATED measure: Validate the differential expression of LOX-1 and NALP3 receptors. measure: Characterize phenotypic alterations. measure: Evaluate the predictive and/or prognostic value. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Institute - IFO - status: RECRUITING city: Rome state: RM zip: 00144 country: Italy name: Benito Chiofalo, Doctor role: CONTACT phone: ND email: benito.chiofalo@ifo.gov.it name: Valentina Bruno, Doctor role: CONTACT phone: ND email: valentina.bruno@ifo.gov.it lat: 41.89193 lon: 12.51133 facility: "Regina Elena" National Cancer Institute status: RECRUITING city: Rome zip: 00144 country: Italy name: Benito Chiofalo, Doctor role: CONTACT phone: ND email: benito.chiofalo@ifo.it name: Valentina Bruno, Doctor role: CONTACT phone: ND email: valentina.bruno@ifo.gov.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06273865 id: HEMSTOL77 briefTitle: Version Testing of EnzySystem Version A for Hemophilia A overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-10-15 date: 2024-12-15 date: 2024-02-23 date: 2024-02-23 name: Radboud University Medical Center class: OTHER name: Enzyre B.V. briefSummary: Background of the study:
To measure blood clotting, blood is taken from a vein. This blood is processed in the laboratory and then tested. A new device has been developed that requires only a very small volume of blood (5-10 drops of blood) to perform the laboratory tests. The long-term goal is that this device can be used by a doctor or at home to quickly measure blood clotting. In this research we want to compare this new system with the standard methods - measurement in the laboratory - and evaluate whether the correct value is determined.
This is a cross-sectional observational study. All participants are asked to fill a questionnaire prior to blood collection. The blood of healthy volunteers will be collected in an office of Enzyre BV, the blood of patients will be collected in the Radboudumc. Blood collection, by venepuncture, will be conducted by a Radboudumc research nurse or physician of the research team in both locations. In total, four blood tubes with citrate as anticoagulant will be drawn (a total of around 11 mL).
The study population consists of 20 healthy volunteers: evenly distributed between male and female; ages spread over the range from 20 to 70 years old; recruited by Enzyre via advertisement. 20 Patients: 5 severe hemophilia A; 5 moderate hemophilia A; 10 mild hemophilia A; recruited from the Hemophilia Treatment Center (HTC) Nijmegen-Eindhoven-Maastricht (NEM) (location Radboudumc).
* blood group conditions: Hemophilia A studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED name: Several assays measure: Time between venipuncture and EnzySystem assay results measure: Validity of EnzySystem FVIII activity results measure: Validity of EnzySystem thrombin generation results sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Radboud university medical center city: Nijmegen zip: 6525 GA country: Netherlands lat: 51.8425 lon: 5.85278 hasResults: False
nctId: NCT06273852 id: PBL-0405-01 briefTitle: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2025-03 date: 2024-02-23 date: 2024-02-29 name: Pure Biologics S.A. class: INDUSTRY name: Presage Biosciences briefSummary: This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device. conditions: Head and Neck Squamous Cell Carcinoma conditions: Soft Tissue Sarcoma Adult conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This substudy is not blinded. primaryPurpose: BASIC_SCIENCE masking: NONE count: 15 type: ESTIMATED name: PBA-0405 measure: Quantification of Cell Death and Immune Cell Biomarkers by immuno-histochemistry (IHC) and In-Situ Hybridization (ISH) measure: Number of Patients with Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06273839 id: B3461114 briefTitle: A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-27 date: 2024-05-27 date: 2024-05-27 date: 2024-02-23 date: 2024-04-02 name: Pfizer class: INDUSTRY briefSummary: The purpose of this clinical trial is to compare the amount of tafamidis in the blood of healthy adult participants after taking three different forms of tafamidis by mouth. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 12 type: ACTUAL name: Tafamidis 61 mg free acid tablet (Test 1) name: Tafamidis 70 mg free acid tablet (Test 1) name: Tafamidis 61 mg free acid capsule (Reference) measure: Area under the concentration-time curve (AUCinf) measure: Maximum observed plasma concentration (Cmax) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pfizer Clinical Research Unit - Brussels city: Brussels state: Bruxelles-capitale, Région DE zip: B-1070 country: Belgium lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06273826 id: 01 briefTitle: "Colorectal Leakage App" for Early Detection of Anastomotic Leakage After Colorectal Surgeries overallStatus: RECRUITING date: 2024-01-19 date: 2025-01 date: 2025-05 date: 2024-02-23 date: 2024-02-23 name: National Research Oncology and Transplantology Center, Kazakhstan class: OTHER briefSummary: The aim of this prospective observational study is to evaluate the effectiveness of the mobile application "Colorectal Leakage App" in the early diagnosis of anastomotic leakage after colorectal surgeries at the National Research Oncology Center in Astana, Kazakhstan.
Participants in the study, individuals aged 18 and above undergoing colorectal surgeries, will be monitored by the mobile application "Colorectal Leakage App" in the postoperative period for early identification of anastomotic leakage. conditions: Anastomotic Leak Large Intestine conditions: Anastomotic Leak Rectum studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: "Colorectal Leakage App" measure: Diagnostic effectiveness of "Colorectal Leakage App". measure: Frequency of anastomotic leakage after colorectal surgeries. measure: Mortality within 30 days measure: Delay in the diagnosis of anastomotic leakage measure: Duration of hospital stay. measure: Number of days in the ICU. measure: Number of days between surgery and detection of AL. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Research Oncology Center status: RECRUITING city: Astana zip: 010000 country: Kazakhstan name: Saule Khamzina, MD role: CONTACT phone: +77757172961 email: khamzina.saule88@gmail.com lat: 51.1801 lon: 71.44598 hasResults: False
nctId: NCT06273813 id: NOV-1776-CL-101 briefTitle: Treatment of Topical Ketorolac Gel in Acute Gouty Flare overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-12 date: 2024-12 date: 2024-02-23 date: 2024-02-23 name: Novilla Pharmaceuticals class: INDUSTRY briefSummary: This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac tromethamine injection, USP (15mg/mL) comparator in healthy volunteers, including an evaluation of safety, tolerability, and efficacy in gout participants with flare-up. conditions: Acute Gouty Arthritis conditions: Acute Pain conditions: Gout Flare studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: All cohost 1 subjects receive single ketorolac tromethamine injection, followed by escalating doses of ketorolac tromethamine gel Cohort 2 and 3 subjects receive doses of ketorolac tromethamine gel for 5 days primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Ketorolac Tromethamine 15 MG/ML name: Ketorolac Tromethamine measure: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 measure: Area Under the Plasma Concentration Versus Time Curve (AUC) of topical ketorolac tromethamine sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Paratus Clinical, city: Blacktown zip: 2148 country: Australia name: Rahul Rahul role: CONTACT phone: +61 1300 742 326 email: info@paratusclinical.com name: Rahul Rahul role: PRINCIPAL_INVESTIGATOR lat: -33.76667 lon: 150.91667 facility: Linear Clinical Research Ltd city: Nedlands zip: 6009 country: Australia name: Jasmine Williams role: CONTACT phone: +61 8 6382 5100 lat: -31.98184 lon: 115.8073 hasResults: False
nctId: NCT06273800 id: M23CMC briefTitle: Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients acronym: Chemosense overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2035-07-15 date: 2036-07-15 date: 2024-02-23 date: 2024-03-29 name: The Netherlands Cancer Institute class: OTHER briefSummary: This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: collection of serum sample blood at first day of neo adjuvant treatment primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Blood sample measure: pCR rate measure: Radiological reduction on tumor size measure: Pathological reduction on tumor size measure: Residual cancer burden (RCB) measure: Distant recurrence free interval (DRFI) measure: Recurrence-free interval (RFI) measure: Overall survival (OS) sex: FEMALE minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT facility: Antoni van Leeuwenhoek city: Amsterdam state: Noord-Holland zip: 1066CX country: Netherlands name: Laura Bornes, PhD role: CONTACT name: Veerle Geurts, PhD role: CONTACT name: Marleen Kok, MD role: PRINCIPAL_INVESTIGATOR lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06273787 id: Mitu briefTitle: Effect of Diaphragmatic Release in Sleep Quality During Pregnancy overallStatus: RECRUITING date: 2023-11-01 date: 2024-02-29 date: 2024-03-17 date: 2024-02-23 date: 2024-02-23 name: MTI University class: OTHER briefSummary: Sleep disordered breathing (SDB) is very common during pregnancy, and is most likely explained by hormonal, physiological and physical changes. Maternal obesity, one of the major risk factors for SDB, together with physiological changes in pregnancy may predispose women to develop SDB. SDB has been associated with poor maternal and fetal outcomes. Thus, early identification, diagnosis and treatment of SDB are important in pregnancy. conditions: SLEEP APNEA PREGNANCY studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment group a : Diaphragmatic Release in addition to positioning instruction group b: positioning instruction primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 44 type: ESTIMATED name: diaphragmatic release measure: pittshurgh sleep quality index measure: diaphragmatic excursion assessment sex: FEMALE minimumAge: 30 Years maximumAge: 40 Years stdAges: ADULT facility: MTI status: RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False